Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma (Aflac-NBL-2002)
A Phase I Study of Allogeneic Ex Vivo Expanded Gamma Delta (γδ) T Cells in Combination With Dinutuximab, Temozolomide, Irinotecan, and Zoledronate in Children With Refractory/ Relapsed, or Progressive Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Sponsor: Emory University
This PHASE1 trial investigates Neuroblastoma and Refractory Neuroblastoma and is currently actively recruiting participants. Emory University leads this study, which shows 13 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1
-
Oct 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
▶ Show 8 earlier versions
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Oct 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Not Yet Recruiting PHASE1
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE1
-
Jul 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
For direct contact, visit the study record on ClinicalTrials.gov .